Camber’s Amlodipine has a Big Impact on the Market
As reported in the Wall Street Journal and the New York Times, Camber Pharma’s Amlodipine, the generic for blood-pressure drug Norvasc has made an immediate and substantial impact on the generics marketplace quickly building a 9 percent share of the overall sales. To view the complete article click the link below.
http://blogs.wsj.com/health/2010/04/05/generic-business-faces-tougher-slog/
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection